Cargando…

Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease

Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in...

Descripción completa

Detalles Bibliográficos
Autor principal: Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888751/
https://www.ncbi.nlm.nih.gov/pubmed/27279757
http://dx.doi.org/10.4137/CCRPM.S23289
_version_ 1782434904079859712
author Suda, Takafumi
author_facet Suda, Takafumi
author_sort Suda, Takafumi
collection PubMed
description Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in approximately 10% of RA patients. Several risk factors, such as old age, male gender, and smoking, have been reported to date. Histologically, the proportion of the usual interstitial pneumonia (UIP) pattern is higher in RA-ILD than in ILD associated with other connective tissue diseases, and RA-ILD also shows nonspecific interstitial pneumonia and organizing pneumonia patterns. High-resolution computed tomography scans are highly predictive of the histological UIP pattern with a specificity of 96%–100%. Acute exacerbation, which is the acute deterioration of the respiratory status characterized by newly developed bilateral infiltrates with unknown etiologies, has been reported in RA-ILD. Although acute exacerbation of RA-ILD has high mortality, similar to that of idiopathic pulmonary fibrosis, its incidence is lower in RA-ILD than in idiopathic pulmonary fibrosis. A consensus treatment has not yet been established. Current therapeutic regimens typically include corticosteroids with or without cytotoxic agents. Recent large longitudinal studies reported that the prognosis of RA-ILD was poor with a median survival of 2.6–3.0 years. Furthermore, histological and/or radiological patterns, such as UIP or non-UIP, have significant prognostic implications. RA-ILD patients with histological or radiological UIP patterns have poorer prognoses than those with non-UIP patterns. This review assessed the characteristics of RA-ILD by overviewing recent studies in the field and focused on the clinical significance of histological and/or radiological patterns in RA-ILD.
format Online
Article
Text
id pubmed-4888751
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-48887512016-06-08 Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease Suda, Takafumi Clin Med Insights Circ Respir Pulm Med Review Pulmonary involvement is common in rheumatoid arthritis (RA) and affects all the components of the lung. Interstitial lung disease (ILD) is the most predominant pulmonary manifestation and has been identified as the main cause of morbidity and mortality in RA. Clinically significant RA-ILD occurs in approximately 10% of RA patients. Several risk factors, such as old age, male gender, and smoking, have been reported to date. Histologically, the proportion of the usual interstitial pneumonia (UIP) pattern is higher in RA-ILD than in ILD associated with other connective tissue diseases, and RA-ILD also shows nonspecific interstitial pneumonia and organizing pneumonia patterns. High-resolution computed tomography scans are highly predictive of the histological UIP pattern with a specificity of 96%–100%. Acute exacerbation, which is the acute deterioration of the respiratory status characterized by newly developed bilateral infiltrates with unknown etiologies, has been reported in RA-ILD. Although acute exacerbation of RA-ILD has high mortality, similar to that of idiopathic pulmonary fibrosis, its incidence is lower in RA-ILD than in idiopathic pulmonary fibrosis. A consensus treatment has not yet been established. Current therapeutic regimens typically include corticosteroids with or without cytotoxic agents. Recent large longitudinal studies reported that the prognosis of RA-ILD was poor with a median survival of 2.6–3.0 years. Furthermore, histological and/or radiological patterns, such as UIP or non-UIP, have significant prognostic implications. RA-ILD patients with histological or radiological UIP patterns have poorer prognoses than those with non-UIP patterns. This review assessed the characteristics of RA-ILD by overviewing recent studies in the field and focused on the clinical significance of histological and/or radiological patterns in RA-ILD. Libertas Academica 2016-05-31 /pmc/articles/PMC4888751/ /pubmed/27279757 http://dx.doi.org/10.4137/CCRPM.S23289 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Review
Suda, Takafumi
Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_full Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_fullStr Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_full_unstemmed Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_short Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_sort up-to-date information on rheumatoid arthritis-associated interstitial lung disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888751/
https://www.ncbi.nlm.nih.gov/pubmed/27279757
http://dx.doi.org/10.4137/CCRPM.S23289
work_keys_str_mv AT sudatakafumi uptodateinformationonrheumatoidarthritisassociatedinterstitiallungdisease